德孚在中国

9 4 3 6 4

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

达沙替尼在慢性粒细胞白血病管理中的作用

 

Authors Chen R, Chen B

Published Date February 2015 Volume 2015:9 Pages 773—779

DOI http://dx.doi.org/10.2147/DDDT.S80207

Received 2 January 2015, Accepted 23 January 2015, Published 9 February 2015

Abstract: Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) for chronic, blastic, or accelerated phase chronic myeloid leukemia (CML) patients who are resistant or intolerant to previous treatment. It potently inhibits BCR/ABL and SRC-family kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK), as well as c-KIT, PDGFR-a and -b, and ephrin receptor kinase. Various clinical trials have provided evidence that it has more durable complete hematologic and cytogenetic responses, as well as more potency in imatinib-resistant or -intolerant CML, and it has also shown its advantages in newly diagnosed CML compared to imatinib. In this review, we mainly focus on the structure, mechanisms, pharmacokinetics, and pharmacogenetics of dasatinib. We also summarize clinical trials with dasatinib on CML and provide our recommendations for dasatinib in the treatment of CML.
Keywords: imatinib, tyrosine kinase inhibitor, clinical trials






Download Article[PDF]